Učitavanje...
Secukinumab: A Review in Psoriatic Arthritis
Secukinumab (Cosentyx(®)) is a fully human monoclonal antibody that selectively targets interleukin (IL)-17A, a proinflammatory cytokine involved in the pathogenesis of psoriatic arthritis (PsA). Administered subcutaneously, the first-in-class anti-IL-17 agent is approved in numerous countries world...
Spremljeno u:
| Izdano u: | Drugs |
|---|---|
| Glavni autor: | |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Springer International Publishing
2021
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8049904/ https://ncbi.nlm.nih.gov/pubmed/33661486 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40265-021-01476-3 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|